Evidence map›Paper›PMID 41422284›Full record

ArticleScientific reports2025

TRIM39 aggravates hepatocellular carcinoma growth through targeting the p62-KEAP1-NRF2 axis.

Tianbao Yang, Zhigang Chen, Fang Yi, Yanhui Yang, Zhijie Chu, Cheng Yang, Longhui Ruan, Junjun Sun, Weifeng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tianbao Yang *Department of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Zhigang Chen *Department of General Surgery, Xiangya School of Medicine, Changde Hospital, Central South University (The first people's hospital of Changde city), Changde, 415000, Hunan Province, China.
Fang YiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Yanhui YangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Zhijie ChuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Cheng YangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Longhui RuanDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Junjun SunDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China.
Weifeng LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, 471003, Luoyang , China. doctoryang@haust.edu.cn.

Funding

the Henan Medical Science and Technology Research and Development Program Project LHGJ20220688
6 · The paper itself

Abstract

The tripartite motif (TRIM) protein family plays important roles in the initiation and progression of various tumors through different mechanisms. However, the biological functions of TRIM39 and its underlying mechanism in hepatocellular carcinoma (HCC) remain largely unknown. In this study, we found that the expression of TRIM39 was increased in HCC tissues compared to adjacent normal tissues and negatively correlated with the prognosis of HCC patients. Functional studies demonstrated that TRIM39 promoted the proliferation of HCC cells in vitro and in vivo. Mechanistically, TRIM39 interacted with p62 and facilitated its ubiquitination, leading to a decrease of p62 protein stability. The downregulation of p62 released KEAP1, which subsequently inhibited NRF2-HO-1 pathway. Moreover, overexpression p62 counteracted the pro-tumor phenotypes induced by TRIM39 in HCC. In conclusion, our study elucidates the oncogenic roles and the relevant mechanisms of TRIM39 in HCC, highlights the TRIM39-p62-Keap1-NRF2 axis in HCC progression. These findings may provide potential therapeutic targets for HCC treatment.

Indexed as

Carcinoma, HepatocellularKelch-Like ECH-Associated Protein 1Liver NeoplasmsNF-E2-Related Factor 2Sequestosome-1 ProteinTripartite Motif ProteinsUbiquitin-Protein LigasesAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceRNA-Binding ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2P62 protein, humanRNA-Binding ProteinsSequestosome-1 ProteinTripartite Motif ProteinsUbiquitin-Protein LigasesHepatocellular carcinomaNRF2P62TRIM39Ubiquitination

Identifiers

PMID41422284
PMCPMC12830633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.